Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/21/2003WO2002024660A1 Imidazole derivatives or their salts
02/21/2003WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/21/2003WO2002016354A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
02/21/2003WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors
02/21/2003WO2002016323A1 Biphenyl derivatives and the use thereof as integrin inhibitors
02/21/2003CA2420945A1 Imidazole derivatives or their salts
02/21/2003CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors
02/21/2003CA2420206A1 Chromenone derivatives and the use thereof for the treatment of diseases in connection with 5-hta1 receptors and/or dopamine d2 receptors
02/21/2003CA2420205A1 Biphenyl derivatives and the use thereof as integrin inhibitors
02/21/2003CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
02/21/2003CA2398766A1 Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
02/20/2003WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use
02/20/2003WO2003014727A1 Remedies for heart diseases
02/20/2003WO2003014322A2 Proteins associated with cell growth, differentiation, and death
02/20/2003WO2003014318A2 Methods for treating diabetes and other blood sugar disorders
02/20/2003WO2003014316A2 Immunomodulatory compositions, formulations, and methods for use thereof
02/20/2003WO2003014315A2 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
02/20/2003WO2003014307A2 Antisense modulation of apolipoprotein(a) expression
02/20/2003WO2003014301A2 Hprp4s as modifiers of the p53 pathway and methods of use
02/20/2003WO2003014300A2 TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
02/20/2003WO2003014299A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
02/20/2003WO2003014296A2 A group of novel anti-cancer compounds with specific structure
02/20/2003WO2003014287A1 Hops extracts, method for the production and use
02/20/2003WO2003014192A1 Quaternary polyamidoamines, the production thereof, corresponding agents and the use thereof
02/20/2003WO2003014165A1 EXTRACTION OF β-GLUCAN FROM CEREALS
02/20/2003WO2003014153A2 Cellular virus receptors and methods of use.
02/20/2003WO2003014145A2 Peptides that bind to atherosclerotic lesions
02/20/2003WO2003014141A1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
02/20/2003WO2003014137A1 Adenosine a3 receptor agonists
02/20/2003WO2003014136A1 11a-AZALIDE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME
02/20/2003WO2003014127A1 Antitumoral analogs
02/20/2003WO2003014125A1 Therapeutically useful tetracyclic ligands
02/20/2003WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists
02/20/2003WO2003014123A1 Tricyclic imidazopyridines
02/20/2003WO2003014122A1 Derivatives of morphine-like opioid compounds
02/20/2003WO2003014120A1 Amino-substituted imidazopyridines for the treatment of gastrointestinal diseases
02/20/2003WO2003014118A1 THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
02/20/2003WO2003014114A2 Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
02/20/2003WO2003014111A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014110A1 Benzazepine derivative, process for producing the same, and use
02/20/2003WO2003014108A1 New quinoline carboxylic acid derivatives substituted by 7-(aminomethyl-5-azospiro[2,4]heptane) and their prepartion method
02/20/2003WO2003014105A1 Bicyclic compound, production and use as hiv inhibitors
02/20/2003WO2003014102A1 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
02/20/2003WO2003014101A1 Hydroxamic acid derivatives
02/20/2003WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014097A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity
02/20/2003WO2003014095A1 Acylaminothiazole derivatives, their preparation and therapeutic use
02/20/2003WO2003014094A2 Heterocyclic aryl sulphonamides
02/20/2003WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
02/20/2003WO2003014091A1 Pyrimidine derivatives as selective inhibitors of cox-2
02/20/2003WO2003014090A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
02/20/2003WO2003014086A1 Process for the preparation of amorphous form of torsemide
02/20/2003WO2003014085A1 Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride
02/20/2003WO2003014084A1 Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
02/20/2003WO2003014083A1 Spiro compounds
02/20/2003WO2003014082A1 Cyclopenta ` b ! indole derivatives as spla2 inhibitors
02/20/2003WO2003014080A2 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
02/20/2003WO2003014079A1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
02/20/2003WO2003014075A2 Novel gamma secretase inhibitors
02/20/2003WO2003014073A1 Fatty acid compounds, preparation and uses thereof
02/20/2003WO2003014064A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
02/20/2003WO2003014063A2 Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof
02/20/2003WO2003013656A2 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis
02/20/2003WO2003013655A2 Carbonic anhydrase inhibitors
02/20/2003WO2003013633A1 Inhalation device with a pharmaceutical composition
02/20/2003WO2003013614A1 Collagen-containing oral preparations, drugs and quasi drugs
02/20/2003WO2003013612A1 Polysaccharide-containing compositions and use thereof
02/20/2003WO2003013611A1 Percutaneous absorption preparations
02/20/2003WO2003013610A2 Surfactant compounds and uses thereof
02/20/2003WO2003013609A1 Sustained-release medicines
02/20/2003WO2003013608A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR
02/20/2003WO2003013607A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
02/20/2003WO2003013606A1 Thrombomodulin-containing medicinal compositions
02/20/2003WO2003013605A1 Remedies for prostatic diseases
02/20/2003WO2003013595A1 Compounds and methods for the modulation of immune responses
02/20/2003WO2003013587A1 Compositions for vascular occlusion
02/20/2003WO2003013572A1 Treatment of tuberculosis using immunomodulator compounds
02/20/2003WO2003013571A1 Peptidomimetics of biologically active metallopeptides
02/20/2003WO2003013566A1 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
02/20/2003WO2003013563A2 Mineral-protein preparations (mpp) and neuropathies in diabetes
02/20/2003WO2003013562A1 Artichoke leaf extracts
02/20/2003WO2003013561A1 Oral compositions for the treatment of scalp disorders
02/20/2003WO2003013559A1 Bile acid absorbent/adsorbent
02/20/2003WO2003013556A1 Medicinal compositions having effects of ameliorating eye diseases and holding eye functions
02/20/2003WO2003013555A1 Method for amplifying expression from a cell specific promoter
02/20/2003WO2003013554A2 Aromatase inhibitors from broussonetia papyrifera
02/20/2003WO2003013552A1 Embolic materials comprising of chitin and/or chitosan and method for preparing thereof
02/20/2003WO2003013551A1 G protein-coupled receptor assay
02/20/2003WO2003013550A1 Micronutrient phosphates as dietary and health supplements
02/20/2003WO2003013549A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
02/20/2003WO2003013548A1 Medical composition for external use for dermatosis
02/20/2003WO2003013546A1 Hypoglycemic agent
02/20/2003WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits
02/20/2003WO2003013544A1 Antiviral medicament for use in controlling white spot syndrome in shrimp
02/20/2003WO2003013543A1 Treatment or prevention of acute renal failure
02/20/2003WO2003013542A1 Asymmetric synthesis of kavalactones
02/20/2003WO2003013541A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
02/20/2003WO2003013540A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
02/20/2003WO2003013539A1 Neuroprotective drug
02/20/2003WO2003013538A1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent
1 ... 5555 5556 5557 5558 5559 5560 5561 5562 5563 5564 5565 5566 5567 5568 5569 5570 5571 5572 5573 5574 5575 ... 7860